Enliven Therapeutics (NASDAQ:ELVN) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Enliven Therapeutics (NASDAQ:ELVN) from a hold rating to a sell rating in a research report released on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Stock Performance

ELVN opened at $29.50 on Friday. The business’s fifty day moving average is $24.29 and its two-hundred day moving average is $21.62. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -16.03 and a beta of 0.33. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.22.

Insider Buying and Selling

In related news, COO Anish Patel sold 48,300 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Richard A. Heyman sold 1,230 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the sale, the director directly owned 22,647 shares in the company, valued at $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 233,843 shares of company stock worth $6,145,489. 25.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP purchased a new stake in shares of Enliven Therapeutics in the fourth quarter valued at $180,000. Invesco Ltd. grew its holdings in Enliven Therapeutics by 7.0% in the 4th quarter. Invesco Ltd. now owns 24,720 shares of the company’s stock valued at $381,000 after buying an additional 1,624 shares during the period. XTX Topco Ltd increased its stake in shares of Enliven Therapeutics by 472.6% during the 4th quarter. XTX Topco Ltd now owns 60,702 shares of the company’s stock valued at $935,000 after acquiring an additional 50,101 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the period. Finally, Virtus Investment Advisers LLC boosted its position in shares of Enliven Therapeutics by 172.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 15,778 shares of the company’s stock worth $243,000 after acquiring an additional 9,991 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.